Pricing Log in Create free account
Saturday 17 October 2026 Export ATYR’s income statement to Excel — free account

aTyr Pharma, Inc.

ATYR Healthcare Biotechnology

aTyr Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $190,000.00, down 19.1% from fiscal 2024. In the quarter to June 2026, revenue fell 90.8%, EPS grew 50.0%, free cash flow grew 32.2% and total debt fell 94.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.17 0.01 −5.56%
Market cap
$18.0M
P/E
0.0×
Fwd P/E
−0.9×
Dividend yield
—
F-score
2/9
Altman Z
−9.34
Beneish M
−3.76
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.05
Total sells 0.01
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — 1 — — — — —
Sell — — — 3 — — — — — — — —
Insider Ownership 4.39%

Capital & Financial Ratios $m

Market Cap 18.03
Revenue 11.16
Net Income (60.81)
Free Cash Flow (54.81)
Net Debt (57.38)
Current Ratio 5.12 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (0.90) (negative: loss-making)
P/S ratio 1.49
P/B ratio 0.34
Past 5Y EPS Growth —
This Y EPS Growth 43.12% (at or above 15%: strong)
Next Y EPS Growth 2.47%
Next Y revenue growth 916.32% (at or above 10%: strong)
Next 5Y EPS Growth 22.90% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −3.4×, against a ten-year median of 0.8×; over the ten years it ranged from −3.4× in 2026 to 31.3× in 2025.
P/S against its own 10 years 0.06%
10-year low 10-year high
P/B against its own 10 years 1.18%
10-year low 10-year high
EV/FCF against its own 10 years 84.99%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 98 72 79 57
Receivables 2 2 1 0
Inventory — — — —
Other — — — —
103 82 80 58
2023 2024 2025 Q'26
Payables 4 4 4 3
ST’ Debt — — — —
Other — — — —
16 15 15 11

Compound Annual Growth %

10y 5y 3y
Sales — (14.75%) (73.65%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (5.22%) 16.40% (1.90%)

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — 0 — 0
’24 0 — — — 0
’23 — — 0 — 0
’22 — — — 10 10
’20 8 0 0 2 10
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (13) (9) — — —
’25 (15) (14) (20) (12) (62)
’24 (22) (20) (13) (13) (69)
’23 (1) (12) (10) (11) (33)
’22 (10) (9) (12) (10) (42)
’21 (6) (8) (11) (8) (33)
’20 2 (6) (6) (5) (15)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (13) (9) — — —
’25 (15) (14) (21) (12) (62)
’24 (22) (20) (13) (13) (69)
’23 (2) (14) (10) (11) (37)
’22 (10) (9) (13) (11) (43)
’21 (6) (8) (12) (8) (33)
’20 2 (6) (6) (5) (15)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.11) (0.11) — — —
’25 (0.17) (0.22) (0.26) (0.14) (0.80)
’24 (0.23) (0.23) (0.23) (0.18) (0.86)
’23 (0.29) (0.22) (0.20) (0.25) (0.94)
’22 (0.44) (0.44) (0.46) (0.26) (1.60)
’21 (0.51) (0.64) (0.42) (0.31) (1.77)
’20 0.25 (0.69) (0.68) (0.47) (1.77)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 29.40 31.50 5.25 2.76 2.13 3.48 2.00 1.08 1.39 0.64

Analyst estimates 2026–2028

Powerpack
High 134.82 90.94 59.14 10.08 7.62 13.10 8.25 2.70 3.98 7.29
People
People Employees 58 65 42 44 43 53 70 59 59 58
Revenue/emp, $m 0.00 0.00 0.00 0.01 0.24 0.00 0.15 0.01 0.00 0.00
Income, $m
Income, $m Revenue — — — 0 10 — 10 0 0 0
Gross margin, % 0.00 0.00 0.00 100.00 100.00 0.00 100.00 100.00 100.00 100.00
EBT (58) (48) (35) (24) (16) (34) (45) (50) (64) (74)
EBT margin, % 0.00 0.00 0.00 (5,631.04) (155.24) 0.00 (436.58) (14,276.77) (27,243.40) (39,012.11)
Net income (58) (48) (35) (24) (16) (34) (45) (50) (64) (74)
Depreciation 2 1 1 2 2 2 2 0 (1) 0
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.13 1.14 0.00 0.37 0.01 0.00 0.00
Earnings (34.17) (26.19) (16.11) (7.03) (1.77) (1.77) (1.60) (0.94) (0.86) (0.80)
Cash flow (31.26) (22.96) (14.50) (5.96) (1.67) (1.73) (1.47) (0.62) (0.93) (0.67)
Capex (0.35) (0.71) (0.28) (0.01) (0.02) (0.01) (0.05) (0.08) 0.00 0.00
Free cash flow (31.62) (23.67) (14.78) (5.97) (1.69) (1.74) (1.53) (0.70) (0.93) (0.67)
Book value 37.14 34.82 15.71 6.27 3.44 5.72 2.51 1.69 0.94 0.72
Shares, m 2 2 2 3 9 19 28 54 74 93
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 — 0.00 0.00 0.00 0.00
P/S — — — 0.00 3.40 — 5.25 6.21 20.64 6.50
P/B — — — 0.67 1.13 — 0.94 0.89 3.85 1.08
EV/Sales — — — 0.00 0.79 — 0.39 (1.03) 15.40 (0.25)
EV/FCF — — — 0.27 (0.54) — (0.12) 0.35 (2.90) 0.05
Cash, $m
Cash, $m Operating cash flow (53) (42) (31) (20) (15) (33) (42) (33) (69) (62)
Capex (1) (1) (1) 0 0 0 (1) (4) 0 0
Free cash flow (53) (44) (32) (20) (15) (33) (43) (37) (69) (62)
Balance, $m
Balance, $m Working capital 66 77 40 19 30 108 67 87 67 65
Total debt 10 20 16 2 1 0 1 1 1 0
Net debt (63) (65) (34) (29) (30) (108) (65) (97) (71) (78)
Shareholders’ equity 63 64 34 21 31 109 71 90 70 67
Returns, %
Returns, % ROA (55.05) (56.75) (48.58) (53.08) (43.31) (43.78) (42.91) (46.56) (58.88) (78.09)
ROIC (18,959.42) 0.00 (15,194.44) 0.00 (847.77) (1,318.00) (471.97) 0.00 0.00 0.00
ROE (65.06) (75.89) (70.52) (86.34) (61.80) (48.03) (50.26) (62.30) (79.88) (108.11)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2025

Charts ten years each

aTyr Pharma, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
COCP Cocrystal Pharma, Inc. $19.8M — (loss-making) — (loss-making) −81.05% (below 0%: shrinking) n/m −16.75% (below 0%: shrinking) 100.00% (3,032.38%) Compare
ATYR aTyr Pharma, Inc. $18.0M — (loss-making) — (loss-making) −90.75% (below 0%: shrinking) n/m +32.22% (above 0%: growing) 100.00% 0.00%
NEUP Neuphoria Therapeutics Inc. $17.9M — (loss-making) — (loss-making) −107.32% (below 0%: shrinking) n/m +133.86% (above 0%: growing) 100.00% 0.00% Compare
JSPR Jasper Therapeutics, Inc. $17.7M — (loss-making) — — n/m +55.74% (above 0%: growing) 0.00% 0.00% Compare
ANEB Anebulo Pharmaceuticals, Inc. $17.6M — (loss-making) — — n/m +6.58% (above 0%: growing) — 0.00% Compare
ACGN Aceragen, Inc. $17.1M — (loss-making) — (loss-making) +2,394.95% (above 0%: growing) n/m −115.67% (below 0%: shrinking) 100.00% (834.33%) Compare
RADX Radiopharm Theranostics Limited - Sponsored ADR $17.0M — — — — −137.75% (below 0%: shrinking) — — Compare
DYAI Dyadic International Inc. $16.8M — (loss-making) — (loss-making) −0.57% (below 0%: shrinking) n/m −1,298.54% (below 0%: shrinking) (2.39%) (213.73%) Compare
PBM Psyence Biomedical Ltd. $16.5M 0.2× — — n/m −707.20% (below 0%: shrinking) — 0.00% Compare
Median of peers $17.4M — — −40.81% — −66.21% 100.00% 0.00%

All 614 Biotechnology stocks →

aTyr Pharma, Inc. (ATYR) key facts

  • Concern: aTyr Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $190,000.00, down 19.1% from fiscal 2024.
  • aTyr Pharma, Inc. (ATYR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, ATYR traded at $0.17, a market capitalization of $18.0 million.
  • Return on equity was −108.1% and debt-to-equity 0.00.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −9.34 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

aTyr Pharma, Inc. (ATYR) Latest News

16 Sep

Impact 5 ·
stockrow.com/ATYR · Data as of Sep 30, 2025 · For information only; not investment advice. · © 2026 stockrow.com